Sheba Medical Center
sheba.co.ilTotal trials
672
Active
43
Phase 3
35
Total enrollment
2,794,504
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 26 of 26 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Carbetocin | — | — | — | — | — | 1 | |
| Teprotumumab Injection [Tepezza] | — | — | — | — | — | 1 | |
| Intravenous Ampicillin followed by Oral Amoxicillin | — | — | — | — | — | 1 | |
| Ampicillin/Amoxicillin plus single-dose PO Azithromycin | — | — | — | — | — | 1 | |
| Oxytocin | — | — | 4 | ||||
| Fludarabine | — | — | — | — | — | 3 | |
| Nivolumab | — | — | — | — | 2 | ||
| ipilimumab | — | — | — | — | 2 | ||
| IL-2 | — | — | — | — | — | 2 | |
| Cyclophosphamide | — | — | — | — | — | 2 | |
| MDMA HCl | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Tremelimumab | — | — | — | — | — | 1 | |
| Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO] | — | — | — | — | — | 1 | |
| Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] | — | — | — | — | — | 1 | |
| TIL | — | — | — | — | — | 1 | |
| FMT Protocol | — | — | — | — | — | 1 | |
| CAR-BCMA | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Open Label Clemastine with a blinded randomize withdrawal | — | — | — | — | — | 1 | |
| SHB-02-CD19 | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | 2 | ||
| Oral contraceptive pills | — | — | — | — | — | 1 | |
| Paromomycin | — | — | — | — | — | 1 | |
| S (+) Ketamine | — | — | — | — | — | 1 |
Next readouts
- 2023-11
- 2024-09-01
- 2025-01-01
- 2026-05
- 2026-06
- 2026-09
- 2026-12
- 2027-03-30
- 2028-01
- 2028-03-01
Top conditions
- Schizophrenia14
- Coronary Artery Disease11
- Multiple Sclerosis9
- Healthy9
- Stroke8
- Pregnancy7
- Major Depressive Disorder7
- Heart Failure6
Frequently asked questions about Sheba Medical Center
- How many clinical trials does Sheba Medical Center have on ClinicalTrials.gov?
- Sheba Medical Center is listed as the lead sponsor on 672 clinical trials in ClinicalTrials.gov, 43 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sheba Medical Center's trials are in Phase 3?
- 35 of Sheba Medical Center's trials are in Phase 3, spread across 26 active drug programs.
- What therapeutic areas does Sheba Medical Center focus on?
- Sheba Medical Center's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Coronary Artery Disease, Multiple Sclerosis, Healthy, Stroke.
- When are Sheba Medical Center's next clinical trial readouts?
- Sheba Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer”, expected around 2023-11.